Linked Life Data

18797450

Source:http://linkedlifedata.com/resource/pubmed/id/18797450

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18797450rdf:typepubmed:Citationlld:pubmed
pubmed-article:18797450lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:18797450lifeskim:mentionsumls-concept:C0025202lld:lifeskim
pubmed-article:18797450lifeskim:mentionsumls-concept:C0376659lld:lifeskim
pubmed-article:18797450lifeskim:mentionsumls-concept:C1517365lld:lifeskim
pubmed-article:18797450lifeskim:mentionsumls-concept:C0205390lld:lifeskim
pubmed-article:18797450lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:18797450lifeskim:mentionsumls-concept:C0205179lld:lifeskim
pubmed-article:18797450lifeskim:mentionsumls-concept:C1522673lld:lifeskim
pubmed-article:18797450pubmed:issue12lld:pubmed
pubmed-article:18797450pubmed:dateCreated2008-11-21lld:pubmed
pubmed-article:18797450pubmed:abstractTextGranulocyte-macrophage colony-stimulating factor (GM-CSF) enhances immune responses by inducing proliferation, maturation, and migration of dendritic cells (DCs) as well as expansion and differentiation of B and T lymphocytes. The potency of DNA vaccines can be enhanced by the addition of DNA encoding cytokines, acting as molecular adjuvants. We conducted a phase I/II trial of human GM-CSF DNA in conjunction with a multipeptide vaccine (gp100 and tyrosinase) in stage III/IV melanoma patients. Nineteen human leukocyte antigen (HLA)-A*0201+ patients were treated. Three dose levels were studied: 100, 400, and 800 microg DNA/injection, administered subcutaneously every month with 500 microg of each peptide. In the dose-ranging study, three patients were treated at each dose level. The remaining patients were then treated at the highest dose. Most toxicities were grade 1 injection-site reactions. Eight patients (42%) developed CD8+ T-cell responses, defined by a > or =3 SD increase in baseline reactivity to tyrosinase or gp100 peptide in tetramer or intracellular cytokine staining (ICS) assays. There was no relationship between dose and T-cell response. Responding T cells had an effector memory cell phenotype. Polyfunctional T cells were also demonstrated. At a median of 31 months follow-up, median survival has not been reached. Human GM-CSF DNA was found to be a safe adjuvant.lld:pubmed
pubmed-article:18797450pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18797450pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18797450pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18797450pubmed:languageenglld:pubmed
pubmed-article:18797450pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18797450pubmed:citationSubsetIMlld:pubmed
pubmed-article:18797450pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18797450pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18797450pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18797450pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18797450pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18797450pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18797450pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18797450pubmed:statusMEDLINElld:pubmed
pubmed-article:18797450pubmed:monthDeclld:pubmed
pubmed-article:18797450pubmed:issn1525-0024lld:pubmed
pubmed-article:18797450pubmed:authorpubmed-author:WangJianJlld:pubmed
pubmed-article:18797450pubmed:authorpubmed-author:KrownSusan...lld:pubmed
pubmed-article:18797450pubmed:authorpubmed-author:HoughtonAlan...lld:pubmed
pubmed-article:18797450pubmed:authorpubmed-author:LivingstonPhi...lld:pubmed
pubmed-article:18797450pubmed:authorpubmed-author:PanageasKathe...lld:pubmed
pubmed-article:18797450pubmed:authorpubmed-author:ZhangYanYlld:pubmed
pubmed-article:18797450pubmed:authorpubmed-author:PeralesMiguel...lld:pubmed
pubmed-article:18797450pubmed:authorpubmed-author:EngelhornManu...lld:pubmed
pubmed-article:18797450pubmed:authorpubmed-author:WolchokJedd...lld:pubmed
pubmed-article:18797450pubmed:authorpubmed-author:ChapmanPaul...lld:pubmed
pubmed-article:18797450pubmed:authorpubmed-author:GonzalezChris...lld:pubmed
pubmed-article:18797450pubmed:authorpubmed-author:GallardoHumil...lld:pubmed
pubmed-article:18797450pubmed:authorpubmed-author:YuanJiandaJlld:pubmed
pubmed-article:18797450pubmed:authorpubmed-author:TerzulliSteph...lld:pubmed
pubmed-article:18797450pubmed:authorpubmed-author:RasalanTeresa...lld:pubmed
pubmed-article:18797450pubmed:authorpubmed-author:EjadiSamuelSlld:pubmed
pubmed-article:18797450pubmed:authorpubmed-author:PowelSarahSlld:pubmed
pubmed-article:18797450pubmed:authorpubmed-author:ManukianGrego...lld:pubmed
pubmed-article:18797450pubmed:issnTypeElectroniclld:pubmed
pubmed-article:18797450pubmed:volume16lld:pubmed
pubmed-article:18797450pubmed:ownerNLMlld:pubmed
pubmed-article:18797450pubmed:authorsCompleteYlld:pubmed
pubmed-article:18797450pubmed:pagination2022-9lld:pubmed
pubmed-article:18797450pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:18797450pubmed:meshHeadingpubmed-meshheading:18797450...lld:pubmed
pubmed-article:18797450pubmed:meshHeadingpubmed-meshheading:18797450...lld:pubmed
pubmed-article:18797450pubmed:meshHeadingpubmed-meshheading:18797450...lld:pubmed
pubmed-article:18797450pubmed:meshHeadingpubmed-meshheading:18797450...lld:pubmed
pubmed-article:18797450pubmed:meshHeadingpubmed-meshheading:18797450...lld:pubmed
pubmed-article:18797450pubmed:meshHeadingpubmed-meshheading:18797450...lld:pubmed
pubmed-article:18797450pubmed:meshHeadingpubmed-meshheading:18797450...lld:pubmed
pubmed-article:18797450pubmed:meshHeadingpubmed-meshheading:18797450...lld:pubmed
pubmed-article:18797450pubmed:meshHeadingpubmed-meshheading:18797450...lld:pubmed
pubmed-article:18797450pubmed:meshHeadingpubmed-meshheading:18797450...lld:pubmed
pubmed-article:18797450pubmed:meshHeadingpubmed-meshheading:18797450...lld:pubmed
pubmed-article:18797450pubmed:meshHeadingpubmed-meshheading:18797450...lld:pubmed
pubmed-article:18797450pubmed:meshHeadingpubmed-meshheading:18797450...lld:pubmed
pubmed-article:18797450pubmed:year2008lld:pubmed
pubmed-article:18797450pubmed:articleTitlePhase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma.lld:pubmed
pubmed-article:18797450pubmed:affiliationDepartment of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.lld:pubmed
pubmed-article:18797450pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:18797450pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:18797450pubmed:publicationTypeClinical Trial, Phase IIlld:pubmed
pubmed-article:18797450pubmed:publicationTypeClinical Trial, Phase Illd:pubmed
pubmed-article:18797450pubmed:publicationTypeResearch Support, N.I.H., Extramurallld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18797450lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18797450lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18797450lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18797450lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18797450lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18797450lld:pubmed